Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats

Psychopharmacology

Volumn 192, Issue 3, 2007, Pages 303-316

  Abekawa, Tomohiro ^a   Ito, Koki ^a   Nakagawa, Shin ^a   Koyama, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

METH; MK 801; NMDA receptor; Parvalbumin; PCP; Prenatal

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; DIZOCILPINE; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PARVALBUMIN; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOPAMINE RELEASE; FEMALE; GABAERGIC SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFRARED RADIATION; LOCOMOTION; MALE; NERVE CELL; NERVE CELL DIFFERENTIATION; NONHUMAN; PATHOGENESIS; PERINATAL PERIOD; PREFRONTAL CORTEX; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROGENY; RAT; SCHIZOPHRENIA; SENSITIZATION; SENSOR;

AGE FACTORS; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GAMMA-AMINOBUTYRIC ACID; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; NEURONS; PARVALBUMINS; PHENCYCLIDINE; PREFRONTAL CORTEX; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 34247855845     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0729-8     Document Type: Article

References (57)

1. 4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats. Psychopharmacology 169:247-256
2. Al-Amin HA, Weickert CS, Weinberger DR, Lipska BK (2001) Delayed onset of enhanced MK-801-induced motor hyperactivity after neonatal lesions of the rat ventral hippocampus. Biol Psychiatry 49:528-539
3. Alcantara S, Ferrer I, Soriano E (1993) Postnatal development of parvalbumin and calbindin D28K immunoreactivities in the cerebral cortex of the rat. Anat Embryol Berl 188:63-73
4. Allen HL, Iversen LL (1990) Phencyclidine, dizocilpine and cerebrocortical neurons. Science 247:221
5. A receptor subunit protein expression in the adult guinea pig cerebral cortex. J Neurosci 21:4381-4389
6. Beasley CL, Reynolds GP (1997) Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 24:349-355
7. Beasley CL, Zhang ZJ, Patten I, Reynolds GP (2002) Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry 52:708-715
8. Behar TN, Scott CA, Greene CL, Wen X, Smith SV, Maric D, Liu QY, Colton CA, Barker JL (1999) Glutamate acting at NMDA receptors stimulates embryonic cortical neuronal migration. J Neurosci 19:4449-4461
9. Benes FM, Bird ED (1987) An analysis of the arrangement of neurons in the cingulate cortex of schizophrenic patients. Arch Gen Psychiatry 44:608-616
10. Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL (1991) Deficits in small interneurons in prefrontal and cingulated cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 48:996-1001
11. A receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 74:1021-1031
12. Bogerts B, Ashtari M, Degreef G, Alvir JMJ, Bilder RM, Lieberman JA (1990) Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Res 35:1-13
13. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wolnlak P, Sommerville W (2003) Effect of divalproex combined with olanzapine or risperidone in patients with acute exacerbation of schizophrenia. Neuropsychopharmacology 28:182-192
14. Celio MR (1990) Calbindin D-28K and parvalbumin in the rat nervous system. Neuroscience 35:375-475
15. Corbett R, Camacho F, Woods AT (1995): Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 120:67-74
16. Csillik A, Okuno E, Csillik B, Knyihar E, Vecsei L (2002) Expression of kynurenine aminotransferase in the subplate of the rat and its possible role in the regulation of programmed cell death. Cereb Cortex 12:1193-1201
17. Cunningham MO, Jones RSG (2000) The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 39:2139-2146
18. Demeulemeester H, Vandesande F, Orban GA, Brando C (1988) Heterogenity of GABAergic cells in cat visual cortex. J Neurosci 8:988-1000
19. Dursun SM, Deakin JF (2001) Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol 15:297-301
20. Farber NB, Wozniak DF, Price MT, Labruyere J, Huss J, St Peter H, Olney JW (1995) Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol Psychiatry 38:788-796
21. Freed WJ, Weinberger DR, Bing LA, Wyatt RJ (1980) Neuropharmacological studies of phencyclidine (PCP)-induced behavioral stimulation in mice. Psychopharmacology 71:291-297
22. Gleason SD, Shannon HE (1997) Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 129:79-84
23. Harris LW, Sharp T, Gartlon J, Jones DNC, Harrison PJ (2003) Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. Eur J Neurosci 18:1706-1710
24. Honack D, Loscher W (1993) Sex differences in NMDA receptor mediated responses in rats. Brain Res 620:167-170
25. Ikonomidou C, Bittigau P, Ishimaru MJ, Wozniak DF, Koch C, Genz K, Pierce MT, Stefovska V, Horster F, Tenkova T, Dikranian K, Olney JW (2000) Ethanol-induced apoptosis neurodegeneration and fetal alcohol syndrome. Science 287:1056-1060
26. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308
27. Jentsch JD, Tran A, Taylor JR, Roth RH (1998) Prefrontal cortical involvement in phencyclidine-induced activation of mesolimbic dopamine system: behavioral and neurochemical evidence. Psychopharmacology 138:89-95
28. Kalivas PW, Hooks MS, Sorg B (1993) The pharmacology and neural circuitry of sensitization to psychostimulants. Behav Pharmacol 4:315-334
29. Komuro H, Rakic P (1993) Modulation of neuronal migration by NMDA receptors. Science 260:95-97
30. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995) Subanesthetic doses of ketamine stimulates psychosis in schizophrenia. Neuropsychopharmacology 13:9-19
31. Leach MJ, Marden CM, Miller AA (1986) Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 27:490-497
32. Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neurons and schizophrenia. Neuroscience 6:312-324
33. Lipska BK, Luu S, Halim ND, Weinberger DR (2002) Behavioral effects of neonatal And adult excitotoxic lesions of the mediodorsal thalamus in the adult rat. Behav Brain Res 141:105-111
34. Loscher W (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58:31-59
35. Malhotra AK, Adler CM, Kennison SD, Elman I, Picker D, Breier A (1997) Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 42:664-668
36. 2A receptors. Eur J Pharmacol 280:R9-R11
37. McPhalen CA, Sielecki AR, Santarsiero BD, James MN (1994): refined crystal structure of rat parvalbumin, a mammalian alpha-lineage parvalbumin, at 2.0 A solution. J Mol Biol 235:718-732
38. Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L (2001) Glutamatergic hypothesis of schizophrenia: clinical research studies with ketamine. Encephale 27:53-59
39. Metin C, Baudoin JP, Rakic S, Parnavelas JG (2006) Cell and molecular mechanisms involved in the migration of cortical interneurons. Eur J Neurosci 23:894-900
40. Millan MJ (2005) N-methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insight and clinical perspectives. Psychopharmacology 179:30-53
41. Moore DB, Quintero MA, Ruygrok AC, Walker DW, Heaton MB (1998) Prenatal ethanol exposure reduces parvalbumin-immunoreactive GABAergic neuronal number in the adult rat cingulated cortex. Neurosci Lett 249:25-28
42. Moy SS, Breese GR (2002) Phencyclidine supersensitivity in rats with neonatal dopamine loss. Psychopharmacology 161:255-262
43. Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007
44. Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates, 3rd edn. Academic, USA
45. Pierce RC, Kalivas PW (1997) A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev 25:192-216
46. Plogmann D, Celio MR (1993) Intracellular concentration of parvalbumin in nerve cells. Brain Res 600:273-279
47. Roberts GW (1991) Schizophrenia: a neuropathological perspective. Br J Psychiatry 158:8-17
48. Robinson TE, Becker JB (1986) Enduring changes in brain and behavior by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 11:157-198
49. Sadikot AF, Burhan AM, Belanger M-C, Sasseville R (1998) NMDA receptor antagonist influences early development of GABAergic interneurons in the mammalian striatum. Dev Brain Res 105:35-42
50. Sato M, Chen C-C, Akiyama K, Otsuki S (1983) Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 18:429-440
51. Seiler N, Grauffel C (1992) Antagonism of phencyclidine-induced hyperactivity in mice by elevated brain GABA concentrations. Pharmacol Biochem Behav 41:603-606
52. Sircar R, Soliman KFA (2003) Effects of postnatal PCP treatment on locomotor behavior and striatal D2 receptor. Pharmacol Biochem Behav 74:943-952
53. Szeszko PR, Bilder RM, Lencz T, Pollack S, Alvir JM, Ashtari M, Wu H, Lieberman JA (1999) Investigation of frontal lobe subregions in first-episode schizophrenia. Psychiatry Res 90:1-15
54. Tiihonen J, Hallikainen T, Ryynanen OP, Repo-Tiihonen E, Kotilainen I, Eronen M, Toivonen P, Wahlbeck K (2003) Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 54:1241-1248
55. Vriend JP, Alexiuk NA (1996) Effects of valproate on amino acid and monoamine concentration in striatum of audiogenic seizureprone Balb/c mice. Mol Chem Neuropathol 27:307-324
56. Wassef AA, Dott SG, Harris A, Brown A, O'Boyle M, Meyer WJ III, Rose RM (2000) Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol 20:357-361
57. Yonezawa Y, Kuroki T, Kawahara T, Tashiro N, Uchimura H (1998) Involvement of γ-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. Eur J Pharmacol 341:45-56